# A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL

> **NCT04841434** · PHASE1,PHASE2 · COMPLETED · sponsor: **Charite University, Berlin, Germany** · enrollment: 18 (actual)

## Conditions studied

- CNS Lymphoma

## Interventions

- **DRUG:** Voraxaze Injectable Product

## Key facts

- **NCT ID:** NCT04841434
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04841434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04841434, "A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04841434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*